Cargando…

Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy

Hormonal manipulation plays a significant role in the treatment of advanced hormone naïve prostate cancer and castration-resistant prostate cancer (CRPC) with or without previous chemotherapy. Combination of gonadotropin releasing hormone (GnRH) agonists and androgen receptor (AR) antagonists (combi...

Descripción completa

Detalles Bibliográficos
Autores principales: Pham, Thy, Sadowski, Martin C., Li, Huika, Richard, Derek J., d’Emden, Michael C., Richard, Kerry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918127/
https://www.ncbi.nlm.nih.gov/pubmed/27340608
http://dx.doi.org/10.1186/s40164-016-0046-1
_version_ 1782439062388342784
author Pham, Thy
Sadowski, Martin C.
Li, Huika
Richard, Derek J.
d’Emden, Michael C.
Richard, Kerry
author_facet Pham, Thy
Sadowski, Martin C.
Li, Huika
Richard, Derek J.
d’Emden, Michael C.
Richard, Kerry
author_sort Pham, Thy
collection PubMed
description Hormonal manipulation plays a significant role in the treatment of advanced hormone naïve prostate cancer and castration-resistant prostate cancer (CRPC) with or without previous chemotherapy. Combination of gonadotropin releasing hormone (GnRH) agonists and androgen receptor (AR) antagonists (combined androgen blockade; CAB) is the first line therapy for advanced hormone naïve prostate cancer, but current strategies are developing novel GnRH antagonists to overcome disadvantages associated with GnRH agonist monotherapy and CAB in the clinical setting. Abiraterone acetate and enzalutamide are hormonal agents currently available for patients with CRPC and are both shown to improve overall survival versus placebo. Recently, in clinical trials, testosterone has been administered in cycles with existing surgical and chemical androgen deprivation therapies (ADT) (intermittent therapy) to CRPC patients of different stages (low risk, metastatic) to abate symptoms of testosterone deficiency and reduce cost of treatment from current hormonal therapies for patients with CRPC. This review will provide an overview on the therapeutic roles of hormonal manipulation in advanced hormone naïve and castration-resistant prostate cancers, as well as the development of novel hormonal therapies currently in preclinical and clinical trials.
format Online
Article
Text
id pubmed-4918127
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49181272016-06-24 Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy Pham, Thy Sadowski, Martin C. Li, Huika Richard, Derek J. d’Emden, Michael C. Richard, Kerry Exp Hematol Oncol Review Hormonal manipulation plays a significant role in the treatment of advanced hormone naïve prostate cancer and castration-resistant prostate cancer (CRPC) with or without previous chemotherapy. Combination of gonadotropin releasing hormone (GnRH) agonists and androgen receptor (AR) antagonists (combined androgen blockade; CAB) is the first line therapy for advanced hormone naïve prostate cancer, but current strategies are developing novel GnRH antagonists to overcome disadvantages associated with GnRH agonist monotherapy and CAB in the clinical setting. Abiraterone acetate and enzalutamide are hormonal agents currently available for patients with CRPC and are both shown to improve overall survival versus placebo. Recently, in clinical trials, testosterone has been administered in cycles with existing surgical and chemical androgen deprivation therapies (ADT) (intermittent therapy) to CRPC patients of different stages (low risk, metastatic) to abate symptoms of testosterone deficiency and reduce cost of treatment from current hormonal therapies for patients with CRPC. This review will provide an overview on the therapeutic roles of hormonal manipulation in advanced hormone naïve and castration-resistant prostate cancers, as well as the development of novel hormonal therapies currently in preclinical and clinical trials. BioMed Central 2016-06-22 /pmc/articles/PMC4918127/ /pubmed/27340608 http://dx.doi.org/10.1186/s40164-016-0046-1 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Pham, Thy
Sadowski, Martin C.
Li, Huika
Richard, Derek J.
d’Emden, Michael C.
Richard, Kerry
Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy
title Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy
title_full Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy
title_fullStr Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy
title_full_unstemmed Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy
title_short Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy
title_sort advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918127/
https://www.ncbi.nlm.nih.gov/pubmed/27340608
http://dx.doi.org/10.1186/s40164-016-0046-1
work_keys_str_mv AT phamthy advancesinhormonaltherapiesforhormonenaiveandcastrationresistantprostatecancerswithorwithoutpreviouschemotherapy
AT sadowskimartinc advancesinhormonaltherapiesforhormonenaiveandcastrationresistantprostatecancerswithorwithoutpreviouschemotherapy
AT lihuika advancesinhormonaltherapiesforhormonenaiveandcastrationresistantprostatecancerswithorwithoutpreviouschemotherapy
AT richardderekj advancesinhormonaltherapiesforhormonenaiveandcastrationresistantprostatecancerswithorwithoutpreviouschemotherapy
AT demdenmichaelc advancesinhormonaltherapiesforhormonenaiveandcastrationresistantprostatecancerswithorwithoutpreviouschemotherapy
AT richardkerry advancesinhormonaltherapiesforhormonenaiveandcastrationresistantprostatecancerswithorwithoutpreviouschemotherapy